Welcome to our dedicated page for Pharma-Bio Serv news (Ticker: PBSV), a resource for investors and traders seeking the latest updates and insights on Pharma-Bio Serv stock.
Pharma-Bio Serv Inc (PBSV) provides essential regulatory consulting and technical services to global life sciences organizations. This page aggregates all official company announcements, press releases, and market-moving developments for investors and industry professionals.
Access curated updates on FDA compliance milestones, technology transfer projects, and strategic partnerships that shape PBSV's operations across pharmaceuticals, biotechnology, and medical devices. Our repository includes earnings disclosures, process validation updates, and laboratory testing advancements through subsidiaries like Scienzalabs and Metrologix.
Bookmark this page for real-time insights into how PBSV navigates complex regulatory landscapes and supports clients in product commercialization. Check regularly for verified updates on operational expansions and quality management innovations in the life sciences sector.
Pharma-Bio Serv (OTCQB:PBSV), a compliance and consulting firm serving pharmaceutical and related industries, reported financial results for Q1 2025. The company achieved revenues of $2.5 million for the quarter ended January 31, 2025, marking a $0.1 million increase compared to the same period last year.
The company reached near breakeven net income, showing significant improvement with a $0.3 million earnings increase year-over-year. The company currently has ongoing projects across Europe, Asia, and Latin America, positioning itself for continued market expansion.
Pharma-Bio Serv (OTCQB:PBSV) reported financial results for the fiscal year ended October 31, 2024. The company experienced a significant decline in performance, with revenues dropping to $9.5 million, representing a decrease of $7.5 million compared to the previous year. The company reported a net loss of $0.8 million, contrasting with a net income of $1.3 million in the prior year.
Despite challenging market conditions, particularly in new investments and projects, the company implemented strategic measures focusing on higher-value services and business development, including technology adoption. The Board of Directors approved a Special Dividend of $0.075 per share, payable around March 20, 2025, demonstrating confidence in their business plan and commitment to shareholder value.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, has announced a special dividend of $0.075 per share. The company, which specializes in regulatory affairs, quality, compliance, project management and technology transfer support, will distribute the dividend on March 20, 2025 to shareholders of record as of February 28, 2025.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm for pharmaceutical and related industries, reported financial results for Q3 2024. The company experienced a significant decline in revenues and profitability. Revenues for the three and nine months ended July 31, 2024, were $2.4 million and $7.2 million respectively, representing decreases of $2.2 million and $6.2 million compared to the same periods last year. The company reported net losses of $0.3 million and $0.8 million for the three and nine-month periods, contrasting with net incomes of $0.5 million and $1.4 million in the previous year. CEO Mr. Sanchez acknowledged industry challenges but highlighted investments in technological tools to identify global business opportunities, aiming to restore profitability and revenue growth.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving various industries including pharmaceuticals, announced a revenue decline for the three and six months ending April 30, 2024. Revenues were $2.4 million and $4.8 million, respectively, marking a decrease of $2.2 million and $4.0 million compared to the same periods last year. The company reported a net loss of $0.2 million and $0.5 million for these periods, compared to net income of $0.4 million and $0.8 million in the previous year. Despite these setbacks, the company is investing in new client relationships and global events to foster growth and stability in the future.
FAQ
What is the current stock price of Pharma-Bio Serv (PBSV)?
What is the market cap of Pharma-Bio Serv (PBSV)?
